Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2014

View Archived Issues

Development of adipocyte-specific lactate receptor inhibitor for the treatment of dyslipidemia

RaQualia Pharma reports data on novel ghrelin receptor agonist

Potentially heat-stable HBV oral vaccine candidate presented

Adjuvanted pertussis vaccine with enhanced protection and thermal stability

Novel homoisoflavonoid analogue for the inhibition of angiogenesis

GSK presents highlights of first quarter 2014

Antipsychotic efficacy of phosphodiesterase inhibition compared with dopamine receptor blockade

Selective lipopeptide nanoparticle-mediated gene silencing of hepatocytes in preclinical models

Novel therapeutic targeting an alternate angiogenic signal pathway

Pre-IBD Consortium formed to research on IBD prevention

Selexys and Cytovance form antibody manufacturing agreement

Double-blind trial finds (S)-(-)-OSU-6162 effective in treating alcohol dependence

Naurex reports topline phase IIb data for GLYX-13 and advances NRX-1074

reMYND's novel diabetes treatment prevents disease progression in mouse model

biOasis peptide vector delivers siRNA to brain

Erytech cleared to begin phase II study ERY-ASP in pancreatic cancer in France

Evotec and Eternygen to identify and develop novel metabolic disease therapy

Ablynx's ALX-0171 completes two further phase I studies

Apitope begins preclinical development for ATX-F8-117

Novel orexin receptor antagonists disclosed by Actelion Pharmaceuticals

Japanese researchers present new agents for cancer

Hoffmann-La Roche discloses novel mGlu5 receptor positive allosteric modulators

Janssen R&D Ireland designs new TLR7/TLR8 receptor agonists

New anticancer agents patented by Chinese scientists

Antiplatelet agent vorapaxar approved by FDA

TGen and George Mason University form genomics and proteomics alliance

Anoro Ellipta approved in E.U. for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...